We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




CSF Immunoassays Aid Diagnosis of Early Alzheimer’s Disease

By LabMedica International staff writers
Posted on 21 Dec 2022

The pathological processes underlying Alzheimer’s disease (AD) begin many years before clinical presentation. More...

Ongoing drug discovery efforts in AD focus on developing disease-modifying treatments aiming to delay onset or progression of dementia and must be initiated early in the disease process.

Cerebrospinal fluid (CSF) biomarkers beta-amyloid (1–42) (Aβ42), phosphorylated tau 181P (pTau181), and total tau (tTau) accurately identify early AD by detecting pathophysiological changes underlying the disease. CSF biomarkers should be measured robustly to aid diagnosis of AD; however, there are difficulties with CSF measurement, including pre-analytical and analytical factors.

Clinical Scientists at the Skåne University Hospital (Malmö, Sweden) and their colleagues assessed the analytical performance of second-generation (Gen II) Elecsys CSF immunoassays (Roche Diagnostics International Ltd, Penzberg, Germany), and adjusted existing cut-offs, to evaluate their potential utility in clinical routine. Samples were analyzed using Elecsys CSF Aβ42, pTau181, and tTau Gen II immunoassays on the Roche Diagnostics’ cobas e 801 analyzer. CSF samples (n>100) were analyzed using a single reagent lot with the three immunoassays on cobas e 801, e 402, e 601, and e 411 analyzers.

The investigators reported that the Gen II immunoassays demonstrated good analytical performance, including repeatability, intermediate precision, lot-to-lot agreement, and platform agreement. Aβ42 Gen I/Gen II immunoassay measurements were strongly correlated. Aβ42 Gen II immunoassay cut-offs were adjusted to 1,030 and 800 ng/L, and pTau181/Aβ42 ratio cut-offs to 0.023 and 0.029, for Gen II and I protocols, respectively. No observations were below the lower limit of the measuring range; above the upper limit, there were none from the AD cohort, and 2.6 and 6.8% from the mild cognitive impairment (MCI) and cognitively normal cohorts, respectively.

The authors concluded that the Elecsys CSF Gen II immunoassays demonstrated good analytical performance on extended cobas e platforms, including precision, lot-to-lot comparisons, and platform agreement, supporting their use in clinical routine to aid diagnosis of early AD. Elecsys CSF Gen II immunoassays provide additional benefits over the Gen I immunoassays, without compromising technical performance. Good technical performance of the immunoassays, plus reduced pre-analytical variability (a result of the new protocol), may provide a solution towards unified biomarker testing and timely diagnosis for patients with early AD. The study was published on October 24, 2022 in the journal Clinical Chemistry And Laboratory Medicine.

Related Links:
Skåne University Hospital
Roche Diagnostics International


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.